336 related articles for article (PubMed ID: 23940586)
1. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
2. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
3. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
6. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
7. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
8. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
9. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
[TBL] [Abstract][Full Text] [Related]
10. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
[TBL] [Abstract][Full Text] [Related]
11. Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo.
Zhou JH; Yao YS; Wang LX; Wang J; Li YH; Jiang MM; Zhou MH; Gao XN; Li RS; Wang LL; Yu L
Chin Med J (Engl); 2013 Dec; 126(23):4552-6. PubMed ID: 24286424
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.
Guo Z; Guo D; Kong D; Bian S; Lin L; Fan S; Li Q; Zhao Y; Jiang Y; Yan J; Wang Z; Sun L; Li Y
Hematology; 2023 Dec; 28(1):2219930. PubMed ID: 37278601
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
[TBL] [Abstract][Full Text] [Related]
14. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
[TBL] [Abstract][Full Text] [Related]
15. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
16. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
[TBL] [Abstract][Full Text] [Related]
18. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.
Shi P; Zhang L; Chen K; Jiang Z; Deng M; Zha J; Guo X; Li P; Xu B
Pharmacogenomics; 2017 Aug; 18(13):1259-1270. PubMed ID: 28745928
[TBL] [Abstract][Full Text] [Related]
19. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]